Impact factor: 9.270*
*2013 Journal Citation Reports® Science Edition (Thomson Reuters, 2014)
Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research. Concise scientific communication is encouraged and peer-reviewed proceedings of international meetings are featured. ARD is the official journal of EULAR.
Impact Factor: 9.270 (Number 1 original research journal in the field of rheumatology)
New Impact Factor
We are delighted to announce that for the fifth consecutive year, ARD remains the number one original research journal in the field of rheumatology, with an Impact Factor of 9.270. Thanks to our authors, readers, reviewers and editorial team for continuing to make ARD the best place to publish rheumatology research.
In the news
Gout linked to heightened diabetes risk and the magnitude of association significantly greater in women
Textbooks from EULAR
Recently published: The EULAR Textbook on Systemic Sclerosis is the most up to date textbook on scleroderma, written by experts from EULAR/EUSTAR.
Also available: The latest edition of the EULAR Textbook on Rheumatic Diseases, the most comprehensive textbook for rheumatologists.
ARD publishes summaries for patients and non-clinicians that clearly explain the findings and treatment implications arising from key research papers published in the journal. Written by BMJ's Best Health team, they are checked for accuracy and readability by the ARD editors and PARE.
RMD Open is a new open access journal from EULAR and BMJ publishing manuscripts on all aspects of rheumatic and musculoskeletal diseases. Now welcoming submissions!